Literature DB >> 23640750

Clinical significance of cell cycle inhibitors in hepatocellular carcinoma.

Yasunobu Matsuda1, Toshifumi Wakai, Masayuki Kubota, Masaaki Takamura, Satoshi Yamagiwa, Yutaka Aoyagi, Mami Osawa, Shun Fujimaki, Ayumi Sanpei, Takuya Genda, Takafumi Ichida.   

Abstract

It is well accepted that cell cycle regulators are strongly implicated in the progression of cancer development. p16 and p27 are potent cyclin-dependent kinase (CDK) inhibitors involved in G1 phase progression, and are regarded as adverse prognostic biomarkers for various types of cancers. It has been reported that the main mechanism for p16 inactivation is aberrant DNA methylation, while p27 is exclusively inactivated by proteasome-mediated protein degradation. We have found that p27 is decreased in around half of hepatocellular carcinomas (HCCs), and in some cases p27 is inactivated by inappropriate interaction with cyclin D1/CDK4 complexes. In such cases, p16 is concomitantly inactivated through DNA methylation. Taking into consideration the complex interaction between p16 and p27, a comprehensive analysis including p16 and p27 would be useful for predicting the prognosis of HCC patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23640750     DOI: 10.1007/s00795-013-0047-7

Source DB:  PubMed          Journal:  Med Mol Morphol        ISSN: 1860-1499            Impact factor:   2.309


  68 in total

Review 1.  Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1.

Authors:  K I Nakayama; S Hatakeyama; K Nakayama
Journal:  Biochem Biophys Res Commun       Date:  2001-04-13       Impact factor: 3.575

2.  Homozygous deletions of the CDKN2 gene and loss of heterozygosity of 9p in primary hepatocellular carcinoma.

Authors:  Z Piao; C Park; J S Lee; C H Yang; K Y Choi; H Kim
Journal:  Cancer Lett       Date:  1998-01-09       Impact factor: 8.679

Review 3.  The regulation of INK4/ARF in cancer and aging.

Authors:  William Y Kim; Norman E Sharpless
Journal:  Cell       Date:  2006-10-20       Impact factor: 41.582

4.  Oncogenic activity of Cdc6 through repression of the INK4/ARF locus.

Authors:  Susana Gonzalez; Peter Klatt; Sonia Delgado; Esther Conde; Fernando Lopez-Rios; Montserrat Sanchez-Cespedes; Juan Mendez; Francisco Antequera; Manuel Serrano
Journal:  Nature       Date:  2006-03-30       Impact factor: 49.962

5.  Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging.

Authors:  F Zindy; D E Quelle; M F Roussel; C J Sherr
Journal:  Oncogene       Date:  1997-07-10       Impact factor: 9.867

Review 6.  Regulation of the cdk inhibitor p27 and its deregulation in cancer.

Authors:  J Slingerland; M Pagano
Journal:  J Cell Physiol       Date:  2000-04       Impact factor: 6.384

7.  Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus.

Authors:  H Kaneto; S Sasaki; H Yamamoto; F Itoh; M Toyota; H Suzuki; I Ozeki; N Iwata; T Ohmura; T Satoh; Y Karino; T Satoh; J Toyota; M Satoh; T Endo; M Omata; K Imai
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

Review 8.  Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.

Authors:  Jiyong Liang; Joyce M Slingerland
Journal:  Cell Cycle       Date:  2003 Jul-Aug       Impact factor: 4.534

9.  p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma.

Authors:  Y Matsuda; T Ichida; J Matsuzawa; K Sugimura; H Asakura
Journal:  Gastroenterology       Date:  1999-02       Impact factor: 22.682

10.  The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma.

Authors:  Ledu Zhou; Yun Huang; Jingdong Li; Zhiming Wang
Journal:  Med Oncol       Date:  2009-03-20       Impact factor: 3.064

View more
  15 in total

Review 1.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

2.  Genetic polymorphisms in apoptosis-related genes and the prognosis of hepatocellular carcinoma.

Authors:  Guo-Peng Yu; Qian-Yi Xiao; Zhu-Qing Shi; Li-Sha Tang; Xiao-Pin Ma; Lu-Yao Zhang; Hai-Tao Chen; Wen-Jia Wang; Peng-Yin Zhang; Dong-Lin Ding; Hui-Xing Huang; Hexige Saiyin; Tao-Yang Chen; Pei-Xin Lu; Neng-Jin Wang; Hong-Jie Yu; Jie-Lin Sun; S Lilly Zheng; Jian-Feng Xu; Long Yu; De-Ke Jiang
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

3.  A novel matrine derivate inhibits differentiated human hepatoma cells and hepatic cancer stem-like cells by suppressing PI3K/AKT signaling pathways.

Authors:  Ying Liu; Yang Qi; Zhi-Hui Bai; Chen-Xu Ni; Qi-Hui Ren; Wei-Heng Xu; Jing Xu; Hong-Gang Hu; Lei Qiu; Jian-Zhong Li; Zhi-Gao He; Jun-Ping Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-10-24       Impact factor: 6.150

4.  Clinical Significance and Prognostic Value of Lactate Dehydrogenase Expression in Cervical Cancer.

Authors:  Yuping Ye; Min Chen; Xinyan Chen; Jingyu Xiao; Lin Liao; Faquan Lin
Journal:  Genet Test Mol Biomarkers       Date:  2022-03

5.  Liver specific expression of Cu/ZnSOD extends the lifespan of Sod1 null mice.

Authors:  Yiqiang Zhang; Yuhong Liu; Michael Walsh; Alex Bokov; Yuji Ikeno; Young C Jang; Viviana I Perez; Holly Van Remmen; Arlan Richardson
Journal:  Mech Ageing Dev       Date:  2016-02-01       Impact factor: 5.432

6.  The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations.

Authors:  Xavier Bisteau; Matias J Caldez; Philipp Kaldis
Journal:  Cancers (Basel)       Date:  2014-01-13       Impact factor: 6.639

7.  The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.

Authors:  Jin-Lan Huang; Shun-Wang Cao; Qi-Shui Ou; Bin Yang; Shi-Hao Zheng; Jing Tang; Jing Chen; Yan-Wei Hu; Lei Zheng; Qian Wang
Journal:  Mol Cancer       Date:  2018-05-26       Impact factor: 27.401

8.  Tumorigenic potential is restored during differentiation in fusion-reprogrammed cancer cells.

Authors:  J Yao; L Zhang; L Hu; B Guo; X Hu; U Borjigin; Z Wei; Y Chen; M Lv; J T Y Lau; X Wang; G Li; Y-P Hu
Journal:  Cell Death Dis       Date:  2016-07-28       Impact factor: 8.469

9.  Upregulation of cyclin-dependent kinase inhibitors CDKN1B and CDKN1C in hepatocellular carcinoma-derived cells via goniothalamin-mediated protein stabilization and epigenetic modifications.

Authors:  Yu-Ting Peng; Wen-Ren Wu; Lih-Ren Chen; Kung-Kai Kuo; Cheng-Hui Tsai; Yu-Ting Huang; Yu-Hsuan Lan; Fang-Rong Chang; Yang-Chang Wu; Yow-Ling Shiue
Journal:  Toxicol Rep       Date:  2015-01-25

10.  Cyclin Y Modulates the Proliferation, Invasion, and Metastasis of Hepatocellular Carcinoma Cells.

Authors:  Kaishun Shi; Qingjing Ru; Chenyi Zhang; Jie Huang
Journal:  Med Sci Monit       Date:  2018-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.